Study Examines Pfizer's COVID-19 Vaccine Against Infection, Hospitalization Over Time

Headline Roundup October 6th, 2021

A study published in the peer-reviewed medical journal The Lancet Monday says that Pfizer-BioNTech's COVID-19 vaccine loses effectiveness over time but remains strong in preventing severe COVID-19 cases. According to the study, which was funded by Pfizer, the vaccine's effectiveness against infection falls from 88% in the first month after inoculation to 47% after five months. However, the study says Pfizer's vaccine remains 90% effective after six months in preventing hospitalization against all COVID-19 variants, including Delta. Researchers analyzed health records of more than 3.4 million people for the study. Last month, the CDC recommended Pfizer's COVID-19 booster shot for people ages 65 and older, and for adults at high risk of severe COVID-19.

Many reports from left-rated outlets highlighted the fact that protection against hospitalization remains strong over time. Conversely, some reports from right-rated outlets highlighted the significant drop-off in the vaccine's effectiveness against infection. Right-rated website Project Veritas published videos Monday that claim to show a Pfizer scientist saying that "antibodies are probably better than the vaccination" for people who had COVID-19 previously.

From the Left
13320

The Pfizer COVID-19 vaccine remains 90% effective at reducing a person's risk of hospitalization from the virus six months after it is administered, a new study has found. This is true even in the face of the delta variant as well as if the person has not received a booster shot.

Still, when it comes to preventing infections, the vaccine's effectiveness wanes rapidly as time passes, the study found. After five months, it is just 47% effective at preventing infection.

In the study, funded by Pfizer, researchers assessed data from Kaiser Permanente and calculated the percentages...

Read full story
From the Center
13320

The effectiveness of Pfizer and BioNTech’s Covid-19 vaccine against infection tumbles over several months, falling from a peak of 88% a month after receiving the two-shot series to 47% six months later, according to an observational study published Monday in the peer-reviewed journal The Lancet.

While the two-dose mRNA vaccine’s efficacy against infection wanes, its protection against Covid-related hospitalizations persists, remaining 90% effective for all coronavirus variants of concern — including delta — for at least six months, according to the study, which was funded by Pfizer.

The findings confirm early reports from...

Read full story
Some content from this outlet may be limited or behind a paywall.
From the Right
13320

The effectiveness of the Pfizer-BioNTech COVID-19 vaccine falls below 50 percent after five months, according to a new study published in The Lancet medical journal on Oct. 4.

The study (pdf), which was funded by Pfizer, aimed to evaluate the overall variant-specific effectiveness of the companies’ vaccine against CCP (Chinese Communist Party) virus infections and COVID-19-related hospital admissions over time.

Researchers analyzed electronic health records of more than 3.4 million men and women who were members of the health care organization Kaiser Permanente Southern California between Dec. 14, 2020, and Aug. 8, and assessed the vaccine effectiveness up...

Read full story
Some content from this outlet may be limited or behind a paywall.